Published in Am J Pathol on June 01, 1999
Developmental context determines latency of MYC-induced tumorigenesis. PLoS Biol (2004) 2.05
A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment. J Clin Invest (2006) 2.02
Genetics of hepatocellular carcinoma. World J Gastroenterol (2007) 1.64
Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2. Cancer Cell (2006) 1.54
Involvement of Myc activity in a G(1)/S-promoting mechanism parallel to the pRb/E2F pathway. Mol Cell Biol (2000) 1.34
Vitamin E reduces chromosomal damage and inhibits hepatic tumor formation in a transgenic mouse model. Proc Natl Acad Sci U S A (2000) 1.04
Oxidative damage, pro-inflammatory cytokines, TGF-alpha and c-myc in chronic HCV-related hepatitis and cirrhosis. World J Gastroenterol (2006) 0.91
Genomic modeling of tumor onset and progression in a mouse model of aggressive human liver cancer. Carcinogenesis (2011) 0.86
Deleted in liver cancer 2 (DLC2) was dispensable for development and its deficiency did not aggravate hepatocarcinogenesis. PLoS One (2009) 0.84
TGF-beta inactivation and TGF-alpha overexpression cooperate in an in vivo mouse model to induce hepatocellular carcinoma that recapitulates molecular features of human liver cancer. Int J Cancer (2010) 0.78
Induction of apoptosis in mouse liver adenoma and carcinoma in vivo by transforming growth factor-beta1. J Cancer Res Clin Oncol (2003) 0.78
A Positive TGF-β/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer. Neoplasia (2016) 0.75
TGF-beta signal transduction. Annu Rev Biochem (1998) 17.83
TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature (1997) 15.75
Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science (1995) 13.15
p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature (1994) 10.95
Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (1995) 9.79
Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell (1994) 9.48
Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell (1996) 8.77
p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev (1994) 8.52
The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature (1998) 5.40
Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med (1997) 5.10
Translational control of p27Kip1 accumulation during the cell cycle. Science (1996) 5.04
Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev (1995) 4.94
Growth inhibition by TGF-beta linked to suppression of retinoblastoma protein phosphorylation. Cell (1990) 3.61
Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med (1997) 3.57
E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J Cell Biol (1998) 2.81
Liver regeneration. 2. Role of growth factors and cytokines in hepatic regeneration. FASEB J (1995) 2.64
Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc. EMBO J (1996) 2.59
Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res (1998) 2.16
A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells. Mol Cell Biol (1994) 2.11
Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis. Cancer Res (1993) 2.09
Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res (1997) 2.05
Cloning and characterization of murine p16INK4a and p15INK4b genes. Oncogene (1995) 2.05
Transforming growth factor beta and cell cycle regulation. Cancer Res (1995) 1.84
Expression of the E2F1 transcription factor overcomes type beta transforming growth factor-mediated growth suppression. Proc Natl Acad Sci U S A (1995) 1.81
Involvement of p21 and p27 in the regulation of CDK activity and cell cycle progression in the regenerating liver. Oncogene (1998) 1.78
Growth inhibition by transforming growth factor beta (TGF-beta) type I is restored in TGF-beta-resistant hepatoma cells after expression of TGF-beta receptor type II cDNA. Proc Natl Acad Sci U S A (1993) 1.64
p27Kip1 overexpression causes apoptotic death of mammalian cells. Oncogene (1997) 1.57
Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res (1997) 1.50
Expression of a dominant negative type II TGF-beta receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development. Oncogene (1998) 1.43
Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology (1995) 1.41
Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. Proc Natl Acad Sci U S A (1997) 1.29
Transforming growth factor-beta 1 inhibits cyclin D1 expression in intestinal epithelial cells. Oncogene (1995) 1.24
Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha. Cancer Res (1998) 1.23
Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res (1997) 1.16
Evolution of neoplastic development in the liver of transgenic mice co-expressing c-myc and transforming growth factor-alpha. Am J Pathol (1996) 1.14
Interspecies comparison of liver carcinogenesis: implications for cancer risk assessment. Carcinogenesis (1997) 1.13
A retinoblastoma-binding protein that affects cell-cycle control and confers transforming ability. Nat Genet (1998) 1.08
Inhibitory effects of transforming growth factor beta 1 on mitogenic response, transforming growth factor alpha, and c-myc in quiescent, well-differentiated colon carcinoma cells. Cancer Res (1990) 1.05
Ras versus cyclin-dependent kinase inhibitors. Curr Opin Genet Dev (1998) 0.99
Imprinted M6p/Igf2 receptor is mutated in rat liver tumors. Oncogene (1998) 0.99
Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin Cancer Res (1996) 0.98
Constitutive expression of mature transforming growth factor beta1 in the liver accelerates hepatocarcinogenesis in transgenic mice. Cancer Res (1997) 0.96
Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model. Proc Natl Acad Sci U S A (1996) 0.94
Overexpression of human cyclin D1 reduces the transforming growth factor beta (TGF-beta) type II receptor and growth inhibition by TGF-beta 1 in an immortalized human esophageal epithelial cell line. Proc Natl Acad Sci U S A (1994) 0.92
Expression of transforming growth factor beta type II receptor reduces tumorigenicity in human gastric cancer cells. Cancer Res (1997) 0.91
Deficient transforming growth factor-beta1 activation and excessive insulin-like growth factor II (IGFII) expression in IGFII receptor-mutant tumors. Cancer Res (1997) 0.89
Regulation of cell cycle-related genes in rat hepatocytes by transforming growth factor beta1. Biochem Biophys Res Commun (1997) 0.81
Overexpression of transforming growth factor beta type I receptor abolishes malignant phenotype of a rat bladder carcinoma cell line. Cell Growth Differ (1997) 0.80
Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene (2009) 3.51
Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A (1995) 3.25
A precursor-product relationship exists between oval cells and hepatocytes in rat liver. Carcinogenesis (1987) 2.98
Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat Genet (1992) 2.63
Acetaminophen-induced hepatic injury: protective role of glutathione in man and rationale for therapy. Clin Pharmacol Ther (1974) 2.62
Cellular distribution of transforming growth factor-beta 1 and procollagen types I, III, and IV transcripts in carbon tetrachloride-induced rat liver fibrosis. J Clin Invest (1990) 2.61
Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res (1998) 2.59
In vivo differentiation of rat liver oval cells into hepatocytes. Cancer Res (1989) 2.58
Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest (1996) 2.42
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene (2012) 2.41
Atypical ductular proliferation and its inhibition by transforming growth factor beta1 in the 3,5-diethoxycarbonyl-1,4-dihydrocollidine mouse model for chronic alcoholic liver disease. Lab Invest (1999) 2.16
Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis. Cancer Res (1993) 2.09
Origin and structural evolution of the early proliferating oval cells in rat liver. Am J Pathol (2001) 2.07
Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China. Cancer Res (1994) 2.06
Expression of stem cell factor and its receptor, c-kit, during liver regeneration from putative stem cells in adult rat. Lab Invest (1994) 1.90
Dose-dependent enzyme induction. Clin Pharmacol Ther (1973) 1.84
Expression of hepatic transcription factors during liver development and oval cell differentiation. J Cell Biol (1994) 1.80
Comparative and integrative functional genomics of HCC. Oncogene (2006) 1.75
The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol (2000) 1.73
Acetaminophen-induced hepatic necrosis. VI. Metabolic disposition of toxic and nontoxic doses of acetaminophen. Pharmacology (1974) 1.70
Origin and fate of oval cells in dipin-induced hepatocarcinogenesis in the mouse. Am J Pathol (1994) 1.67
Changes in liver blood flow during enzyme induction. Biochem Pharmacol (1971) 1.65
Interindividual differences in rates of drug oxidation in man. Drug Metab Dispos (1974) 1.63
Expression of acidic fibroblast growth factor in regenerating liver and during hepatic differentiation. Lab Invest (1992) 1.63
Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology (2000) 1.59
Smoking and industrial pollution, and their effects on menopause and ovarian cancer. Lancet (1978) 1.59
Occurrence of oval-type cells in hepatitis B virus-associated human hepatocarcinogenesis. Hepatology (1992) 1.58
The recombinant proregion of transforming growth factor beta1 (latency-associated peptide) inhibits active transforming growth factor beta1 in transgenic mice. Proc Natl Acad Sci U S A (1996) 1.56
Novel recurrent genetic imbalances in human hepatocellular carcinoma cell lines identified by comparative genomic hybridization. Hepatology (1999) 1.50
Common antigens of mouse oval and biliary epithelial cells. Expression on newly formed hepatocytes. Differentiation (1990) 1.45
Acetaminophen-induced hepatic necrosis. V. Correlation of hepatic necrosis, covalent binding and glutathione depletion in hamsters. Pharmacology (1974) 1.43
Differential effects of transforming growth factor-beta on proliferation of normal and malignant rat liver epithelial cells in culture. Cancer Res (1986) 1.43
Expression of cellular myc and mos genes in undifferentiated B cell lymphomas of Burkitt and non-Burkitt types. Proc Natl Acad Sci U S A (1983) 1.42
Activation of hepatic stem cell compartment in the rat: role of transforming growth factor alpha, hepatocyte growth factor, and acidic fibroblast growth factor in early proliferation. Cell Growth Differ (1993) 1.38
Partial cloning of rat CD34 cDNA and expression during stem cell-dependent liver regeneration in the adult rat. Hepatology (1997) 1.34
Oval cell differentiation into hepatocytes in the acetylaminofluorene-treated regenerating rat liver. Hepatology (1995) 1.33
Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis. Oncogene (2000) 1.33
Precursor-product relationship between oval cells and hepatocytes: comparison between tritiated thymidine and bromodeoxyuridine as tracers. Carcinogenesis (1996) 1.29
Expression of hepatocyte growth factor and c-met genes during hepatic differentiation and liver development in the rat. Am J Pathol (1993) 1.28
Expression of the multidrug-resistant gene in hepatocarcinogenesis and regenerating rat liver. Science (1987) 1.28
The Ah locus and the metabolism of chemical carcinogens and other foreign compounds. Adv Cancer Res (1977) 1.27
Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha. Cancer Res (1998) 1.23
Activation of beta-catenin during hepatocarcinogenesis in transgenic mouse models: relationship to phenotype and tumor grade. Cancer Res (2001) 1.22
Transforming growth factor-beta 1 and type I procollagen transcripts during regeneration and early fibrosis of rat liver. Lab Invest (1990) 1.22
Modulation of keratin 14 and alpha-fetoprotein expression during hepatic oval cell proliferation and liver regeneration. J Cell Physiol (1994) 1.22
Therapeutic antibodies elicited by immunization against TNF-alpha. Nat Biotechnol (1999) 1.21
Role of the IkappaB kinase complex in oncogenic Ras- and Raf-mediated transformation of rat liver epithelial cells. Mol Cell Biol (2000) 1.21
Contribution of CYLN2 and GTF2IRD1 to neurological and cognitive symptoms in Williams Syndrome. Neurobiol Dis (2006) 1.21
Mechanism of hepatic drug oxidation and its relationship to individual differences in rates of oxidation in man. Ann N Y Acad Sci (1971) 1.20
NANOG modulates stemness in human colorectal cancer. Oncogene (2012) 1.19
Reduced growth capacity of hepatocytes from c-myc and c-myc/TGF-alpha transgenic mice in primary culture. Biochem Biophys Res Commun (1996) 1.18
Common antigen of oval and biliary epithelial cells (A6) is a differentiation marker of epithelial and erythroid cell lineages in early development of the mouse. Differentiation (1993) 1.18
Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications. J Hepatol (2010) 1.16
Carcinogenicity of 2-amino-3-methylimidazo[4,5-f]quinoline in nonhuman primates: induction of tumors in three macaques. Jpn J Cancer Res (1990) 1.16
Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res (1997) 1.16
In vivo infusion of growth factors enhances the mitogenic response of rat hepatic ductal (oval) cells after administration of 2-acetylaminofluorene. Hepatology (1996) 1.14
Evolution of neoplastic development in the liver of transgenic mice co-expressing c-myc and transforming growth factor-alpha. Am J Pathol (1996) 1.14
Heterogeneity within animal thioredoxin reductases. Evidence for alternative first exon splicing. J Biol Chem (2000) 1.14
Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia (2008) 1.11
Coinduction of MDR-1 multidrug-resistance and cytochrome P-450 genes in rat liver by xenobiotics. J Natl Cancer Inst (1988) 1.11
Proliferation, apoptosis, and induction of hepatic transcription factors are characteristics of the early response of biliary epithelial (oval) cells to chemical carcinogens. Hepatology (1996) 1.10
In situ hybridization studies on expression of albumin and alpha-fetoprotein during the early stage of neoplastic transformation in rat liver. Cancer Res (1987) 1.10
Nonrandom cytogenetic alterations in hepatocellular carcinoma from transgenic mice overexpressing c-Myc and transforming growth factor-alpha in the liver. Am J Pathol (1999) 1.09
Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction. Br J Cancer (2010) 1.09
Expression of transforming growth factor-alpha in regenerating liver and during hepatic differentiation. Mol Carcinog (1992) 1.09
Cellular and molecular changes in the early stages of chemical hepatocarcinogenesis in the rat. Cancer Res (1990) 1.09
A retinoblastoma-binding protein that affects cell-cycle control and confers transforming ability. Nat Genet (1998) 1.08
Contrasting patterns of regulation of the antioxidant selenoproteins, thioredoxin reductase, and glutathione peroxidase, in cancer cells. Biochem Biophys Res Commun (1998) 1.07
Role of TGF-beta in normal differentiation and oncogenesis in rat liver. Mol Carcinog (1989) 1.07
Disruption of redox homeostasis in the transforming growth factor-alpha/c-myc transgenic mouse model of accelerated hepatocarcinogenesis. J Biol Chem (1998) 1.05
Evidence for a common cell of origin for primitive epithelial cells isolated from rat liver and pancreas. J Cell Physiol (1991) 1.05
Expression of leukemia inhibitory factor and its receptor during liver regeneration in the adult rat. Lab Invest (1996) 1.04
Vitamin E reduces chromosomal damage and inhibits hepatic tumor formation in a transgenic mouse model. Proc Natl Acad Sci U S A (2000) 1.04
Glutathione in the developing mouse liver--I. Developmental curve and depletion after acetaminophen treatment. Biochem Pharmacol (1976) 1.02
Coexpression of C-myc and transforming growth factor alfa in the liver promotes early replicative senescence and diminishes regenerative capacity after partial hepatectomy in transgenic mice. Hepatology (1997) 1.02
Dexamethasone inhibits the proliferation of hepatocytes and oval cells but not bile duct cells in rat liver. Hepatology (1998) 1.02
Alterations of the FHIT gene in human hepatocellular carcinoma. Cancer Res (2000) 1.02
Individual differences in the plasma half-lives of lipid soluble drugs in man. Acta Pharmacol Toxicol (Copenh) (1971) 1.01
Metabolism of food-derived heterocyclic amines in nonhuman primates. Mutat Res (1997) 1.01
Ploidy and karyotypic alterations associated with early events in the development of hepatocarcinogenesis in transgenic mice harboring c-myc and transforming growth factor alpha transgenes. Cancer Res (1996) 1.01
Studies on the mechanism of acetamide hepatocarcinogenicity. Pharmacol Toxicol (1987) 1.00
Detection by immunomagnetic PCR of Mycobacterium avium subsp. paratuberculosis in milk from dairy goats in Norway. Vet Microbiol (2003) 1.00
Breaking of B cell tolerance toward a highly conserved self protein. J Immunol (1996) 1.00
Transformation of rat liver epithelial cells with v-H-ras or v-raf causes expression of MDR-1, glutathione-S-transferase-P and increased resistance to cytotoxic chemicals. Carcinogenesis (1988) 1.00
Expression of transforming growth factor alpha/epidermal growth factor receptor, hepatocyte growth factor/c-met and acidic fibroblast growth factor/fibroblast growth factor receptors during hepatocarcinogenesis. Carcinogenesis (1996) 1.00
Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response. Oncogene (2011) 1.00